Estimated tumor blood flow as a predictive imaging indicator of therapeutic response in pancreatic ductal adenocarcinoma: use of three-phase contrast-enhanced computed tomography

[1] Siegel RL(2021)Cancer statistics, 2021 CA Cancer J Clin 71 7-33

[2] Miller KD(2019)Vimentin expression in tumor microenvironment predicts survival in pancreatic ductal adenocarcinoma: Heterogeneity in fibroblast population Ann Surg Oncol 26 4791-4804

[3] Fuchs HE(2012)Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies Ann Surg Oncol 19 1644-1662

[4] Maehira H(2013)Clinical features and treatment outcome of borderline resectable pancreatic head/body cancer: a multi-institutional survey by the Japanese Society of Pancreatic Surgery J Hepatobiliary Pancreat Sci 20 601-610

[5] Miyake T(2017)Neoadjuvant treatment in pancreatic cancer: evidence-based medicine? A systematic review and meta-analysis Med Oncol 34 85-203

[6] Iida H(2019)A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study J Gastroenterol 54 194-600

[7] Andriulli A(2013)Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery J Hepatobiliary Pancreat Sci 20 590-1057

[8] Festa V(2004)Pancreatic cancer Lancet 363 1049-635

[9] Botteri E(2019)Perfusion CT to assess response to neoadjuvant chemotherapy and radiation therapy in pancreatic ductal adenocarcinoma: Initial experience Radiology 292 628-247

[10] Kato H(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228-1339

[1] Siegel RL(2021)Cancer statistics, 2021 CA Cancer J Clin 71 7-33

[2] Miller KD(2019)Vimentin expression in tumor microenvironment predicts survival in pancreatic ductal adenocarcinoma: Heterogeneity in fibroblast population Ann Surg Oncol 26 4791-4804

[3] Fuchs HE(2012)Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies Ann Surg Oncol 19 1644-1662

[4] Maehira H(2013)Clinical features and treatment outcome of borderline resectable pancreatic head/body cancer: a multi-institutional survey by the Japanese Society of Pancreatic Surgery J Hepatobiliary Pancreat Sci 20 601-610

[5] Miyake T(2017)Neoadjuvant treatment in pancreatic cancer: evidence-based medicine? A systematic review and meta-analysis Med Oncol 34 85-203

[6] Iida H(2019)A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study J Gastroenterol 54 194-600

[7] Andriulli A(2013)Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery J Hepatobiliary Pancreat Sci 20 590-1057

[8] Festa V(2004)Pancreatic cancer Lancet 363 1049-635

[9] Botteri E(2019)Perfusion CT to assess response to neoadjuvant chemotherapy and radiation therapy in pancreatic ductal adenocarcinoma: Initial experience Radiology 292 628-247

[10] Kato H(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228-1339